Search

Displaying results 3271 - 3280 of 10000 in total
  1. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown. … Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women.[L9635] Bremelanotide does not interact with alcohol.

  2. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

  3. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  4. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … , resulting in a premature termination of the trial.

  5. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  6. Drug

    Quinfamide

    go.drugbank.com/drugs/DB12780
    Investigational

    Quinfamide has been used in trials studying the treatment of Amoebiasis and Helminthiasis.

    Mixtures: L-OMBRIX-DUET, L-OMBRIX-DUET
  7. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

  8. Drug

    Vancomycin

    go.drugbank.com/drugs/DB00512
    ApprovedInvestigational

    Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196]. … As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexProducts: INJOVAN®500 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, INJOVAN®1000 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE
  9. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. … Nonacog beta pegol is a recombinant coagulation factor IX derivative.

    Categories: Compounds used in a research, industrial, or household settingProducts: REFİXİA 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, REFİXİA 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR
  10. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. … It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells.